Halozyme Therapeutics, Inc. (NASDAQ:HALO) is a biopharmaceutical company focused on innovative drug delivery technologies, primarily through its Enhaze platform. This technology, based on the rHuPH20 ...

The pharma giant said it has agreed to acquire the U.S. privately held, clinical-stage biopharmaceutical company to boost its ...

The inhaled monoclonal antibody IN-006 shows promise in COVID-19 treatment, with high airway antibody levels and a favorable safety profile in healthy adults.

For decades, lab-made antibodies have been used to support patients fighting specific diseases. These treatments have become ...

Alloy Therapeutics Inc. (“Alloy”), a biotechnology ecosystem company dedicated to democratizing access to cutting edge drug ...

Anthos Therapeutics, based in Cambridge, has a drug in late-stage clinical trials aimed at preventing strokes and blood clots.

In his next chief executive gig after securing the $14 billion acquisition of Karuna Therapeutics Inc., Bill Meury has now locked in another big biotech deal.

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed ...

Novartis is buying Anthos Therapeutics from Blackstone’s drug development division, as it makes a bet on an experimental drug aimed at preventing strokes in patients with an irregular heart rhythm.

Yahoo News provides the latest updates on the spread of bird flu in the U.S., and its effect on rising egg prices and ...